FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

ashington,	D.C.	20549	
asimigton,	D.O.	20040	

CTATEMENIT	OF CHAI	NICES IN	BENEFICIAL	OWNEDCHID
SIAIEMENI	OF CHAI	NGES IIV	DENEFICIAL	OWINERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours ner response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Spray Shelley D</u>					<u>Pul</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol Pulse Biosciences, Inc. [ PLSE ]						(Ch	Relationship leck all appli X Directo	,	) Pers	son(s) to Iss 10% Ow		
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/25/2023							Officer below)	(give title		Other (s below)	pecify	
3957 POINT EDEN WAY					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) HAYWA	.RD C.	A	94545												iled by One iled by More		Ü	
(City)	(S	tate)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication						)						
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Non	-Deriv	ative	Sec	curities	s Ac	quired, D	isp	osed o	of, or Be	neficia	lly Owne	d			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		Transaction Dispose Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		Benefic Owned	es ally Following	Form (D) o		7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D) Price		Reporte Transac (Instr. 3	ction(s)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	Transaction of Code (Instr. 8) Set Act (A) Dis of (Instr. 1)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction( (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$5.95	05/25/2023			A		20,000		(1)	05	5/25/2033	Common Stock	20,000	\$0	20,000		D	

## **Explanation of Responses:**

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023.

/s/ Kenneth B. Stratton, as Attorney-in-Fact

06/06/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.